Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript - Thomson StreetEvents

Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript

Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript - Thomson StreetEvents
Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript
Published Feb 03, 2022
28 pages (14295 words) — Published Feb 03, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CADI.NS earnings conference call or presentation 3-Feb-22 11:00am GMT

  
Brief Excerpt:

...Operator Ladies and gentlemen, good day, and welcome to Cadila Healthcare Limited Q3 FY '22 Post Results Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Ganesh Nayak Executive Director at Cadila Healthcare Limited. Thank you, and over to you, sir. Ganesh Narayan Nayak ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Cadila Healthcare Ltd
Ticker
CADI.NS
Time
11:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Sir, on ZyCoV-D vaccine, just wanted a clarity on pricing. So we have a pricing for government. For private hospital or private suppliers, can you indicate any pricing you have in your mind?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. And so initially, supply would be from your own manufacturing site or Shilpa would also be contributing also next quarter?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. And for a global market, getting it registered in different countries, the responsibility of your partner? Or you need to have -- get approval?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. Okay. And just the last one on desidustat, what's your progress? So we have submitted with the DCGI. Any time line when we can see it coming to the market in India?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. So apart from this, any other meaningful product launches in India from biosimilar side, basically?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Just on biosimilars, the 12 biosimilars currently we have in India. So what would be the contribution of biosimilars in Indian business?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Sorry. It is INR 650 crores, you said? Hello? Hello?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Yes. So am I audible now? Everybody?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Hello?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : And what would be the export revenue of biosimilars? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 03, 2022 / 11:00AM, CADI.NS - Q3 2022 Cadila Healthcare Ltd Earnings Call

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. And secondly, on malarial products. So we had orphan designation. So what process remains to get it rolled out and when we can expect...

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. So being an orphan drug, can we expect it getting the trials to [be] completed in the next 2 years?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay, fine. And of that 505(b)(2) pipeline, so we have some progress on product...

Table Of Contents

Cadila Healthcare Ltd Extraordinary Shareholders Meeting Transcript – 2022-02-18 – US$ 54.00 – Edited Transcript of CADI.NS shareholder or annual meeting 18-Feb-22 4:30am GMT

Cadila Healthcare Ltd Q2 2022 Earnings Call Transcript – 2021-10-29 – US$ 54.00 – Edited Transcript of CADI.NS earnings conference call or presentation 29-Oct-21 10:30am GMT

Cadila Healthcare Ltd to Discuss About the Emergency Use Authorization of ZyCov-D Vaccine Call Transcript – 2021-08-23 – US$ 54.00 – Edited Transcript of CADI.NS conference call or presentation 23-Aug-21 9:30am GMT

Cadila Healthcare Ltd Q1 2022 Earnings Call Transcript – 2021-08-11 – US$ 54.00 – Edited Transcript of CADI.NS earnings conference call or presentation 11-Aug-21 10:30am GMT

Cadila Healthcare Ltd Q4 2021 Earnings Call Transcript – 2021-05-27 – US$ 54.00 – Edited Transcript of CADI.NS earnings conference call or presentation 27-May-21 12:00pm GMT

Cadila Healthcare Ltd to Discuss the Transaction of Zydus Cadila Entity to Sell Its India Focused Animal Health Business to Multiples Alternate Asset Management Call Transcript – 2021-05-12 – US$ 54.00 – Edited Transcript of CADI.NS M&A conference call or presentation 12-May-21 11:00am GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript" Feb 03, 2022. Alacra Store. May 14, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2022-Cadila-Healthcare-Ltd-Earnings-Call-T15104824>
  
APA:
Thomson StreetEvents. (2022). Cadila Healthcare Ltd Q3 2022 Earnings Call Transcript Feb 03, 2022. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2022-Cadila-Healthcare-Ltd-Earnings-Call-T15104824>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.